Hematologic Malignancies
News
Stem cells gene edited to be HIV resistant treat ALL, but not HIV
Commentary
Genomic Medicine and Genetic Counseling in the Department of Veterans Affairs and Department of Defense
Conference Coverage
SC daratumumab deemed feasible for every multiple myeloma patient
CHICAGO – In the COLUMBA trial, subcutaneous daratumumab proved noninferior to intravenous daratumumab in overall response rate and maximum trough...
Latest News
Another study supports safety of 2-cm margins for thick melanomas
Similar outcomes seen with 4-cm and 2-cm excision margins for melanomas greater than 2 mm.
Conference Coverage
Ibrutinib tops chlorambucil against CLL
AMSTERDAM – The Bruton’s tyrosine kinase inhibitor was associated with a halving of risk for death, compared with chlorambucil.
News
Recombinant vaccine cut herpes zoster rate in immunocompromised patients
In a randomized clinical trial of 1,846 adults who had undergone autologous HSCT, herpes zoster cases were seen in 49 and 136 individuals in the...
Latest News
FDA approves Xpovio for relapsed/refractory multiple myeloma
The oral therapy was approved for patients who have received at least four prior therapies and whose disease is resistant to several other forms...
Conference Coverage
Researchers propose new risk groups for NK-AML
NEWPORT BEACH, CALIF. – Investigators used machine learning algorithms to risk stratify patients with normal karyotype acute myeloid leukemia.
News
CAR T-cell therapy bb2121 performs well in phase 1 trial of refractory multiple myeloma
The objective response rate of 85% among 33 heavily pretreated patients suggests “promising efficacy.”